

# Mutations in presenilin 2 and its implications in Alzheimer's disease and other dementia-associated disorders

Yan Cai<sup>1</sup>  
Seong Soo A An<sup>1</sup>  
SangYun Kim<sup>2</sup>

<sup>1</sup>Department of Bionano Technology, Gachon Medical Research Institute, Gachon University, <sup>2</sup>Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea

**Abstract:** Alzheimer's disease (AD) is the most common form of dementia. Mutations in the genes encoding presenilin 1 (*PSEN1*), presenilin 2 (*PSEN2*), and amyloid precursor protein have been identified as the main genetic causes of familial AD. To date, more than 200 mutations have been described worldwide in *PSEN1*, which is highly homologous with *PSEN2*, while mutations in *PSEN2* have been rarely reported. We performed a systematic review of studies describing the mutations identified in *PSEN2*. Most *PSEN2* mutations were detected in European and in African populations. Only two were found in Korean populations. Interestingly, *PSEN2* mutations appeared not only in AD patients but also in patients with other disorders, including frontotemporal dementia, dementia with Lewy bodies, breast cancer, dilated cardiomyopathy, and Parkinson's disease with dementia. Here, we have summarized the *PSEN2* mutations and the potential implications of these mutations in dementia-associated disorders.

**Keywords:** mutations in presenilin 2, Alzheimer's disease

## Introduction

Alzheimer's disease (AD) is the most common form of neurodegenerative disease of the brain. Pathological hallmarks of AD include intraneuronal accumulation of paired helical filaments composed of abnormal tau proteins and extracellular deposits of  $\beta$ -amyloid peptide (A $\beta$ ) in neuritic plaques.<sup>1</sup> Clinically, AD can be categorized into two phenotypes based on the ages of onset: early-onset AD (EOAD; <65 years) and late-onset AD (LOAD; >65 years), of which LOAD is the more common form worldwide. The proportion of EOAD in all AD cases is between 5% and 10%.<sup>2</sup> Presenilin 1 (*PSEN1*), presenilin 2 (*PSEN2*), and amyloid precursor protein (*APP*) are mostly associated with autosomal dominant forms of EOAD.<sup>3</sup> Apart from genetic factors, mutations are environmentally related. Genetic-environmental interactions may be caused by variation in the age of onset, neuropathological patterns, and disease duration.<sup>4</sup> To date, more than 200 mutations have been described in *PSEN1* throughout the world, but mutations in *PSEN2* are extremely rare. Less than 40 mutations in *PSEN2* have been identified.<sup>5</sup> From those, two *PSEN2* mutations were detected in Korean patients. Unlike *PSEN1*, AD patients with *PSEN2* mutations have a wide range in the age of onset, from 40 to 80 years.<sup>6</sup> Interestingly, some reports have suggested that the inherited mode of AD was autosomal inheritance with variable penetrance, which suggests that other environmental factors might also be significant for AD pathogenesis.<sup>7</sup> In addition, mutations in *PSEN2* are also closely involved in other diseases, including EOAD, LOAD, frontotemporal dementia (FTD), dementia with Lewy bodies (DLBs), breast cancer, dilated cardiomyopathy (DCM). In this review,

Correspondence: Seong Soo A An  
Department of Bionano Technology,  
Gachon Medical Research Institute,  
Gachon University, 1342 Seongnam-  
daero, Sujeong-gu, Seongnam-si,  
Gyeonggi-do 461-701, South Korea  
Tel +82 31 750 8755  
Fax +82 31 750 8755  
Email seongan@gachon.ac.kr

SangYun Kim  
Department of Neurology, Seoul  
National University Bundang Hospital,  
300 Gumidong, Bundang-gu, Seongnam-si,  
Gyeonggi-do 463-707, South Korea  
Tel +82 31 787 7462  
Fax +82 31 719 6815  
Email neuroksy@snu.ac.kr

we studied and summarized *PSEN2*, in particular, the known *PSEN2* mutations and the potential implications of *PSEN2* in AD and in other disorders.

## **PSEN2 gene**

In 1995, *PSEN2* was initially reported as a causative gene for AD, following the identification of *APP* and *PSEN1*.<sup>8</sup> The gene was localized to chromosome 1q42.13. It consists of 12 exons, of which exon 1 and exon 2 contain the untranslated regions.

## **PSEN2 transcription**

### **Transcriptional regulation**

*PSEN2* is driven by two separate promoter elements, P1 and P2, which are located in exon 1 and exon 2, respectively. The upstream P1 is a housekeeping promoter. *PSEN2*-P1 activity depends on a stimulating protein 1 binding site at the most 5' initiation site. The downstream P2 is induced by Egr-1, which represses *PSEN2*-P1 activity.<sup>9</sup> Interestingly, a study showed that Egr-1 cannot regulate the *PSEN2* promoter in mouse.<sup>10</sup> *APP* influences the expression of *Egr-1* by enhancing histone H4 acetylation of the *Egr-1* promoter.<sup>11</sup>

### **Splice variant**

The two isoforms of *PSEN2* protein are produced by alternative splicing. An aberrant splice variant of *PSEN2* lacks exon 5, which results in the insertion of five amino acids, SSMAG, into the protein variant, and which introduces a premature stop codon in exon 6.<sup>12</sup> Aggregation of the *PSEN2* variant protein was detected in the hippocampus and cerebral cortex of patients with sporadic AD.<sup>13</sup> The protein variant also was detected in sporadic AD patients, in the frontal lobe of patients with bipolar disorder, and in patients with schizophrenia.<sup>14,15</sup> The *PSEN2* variant is upregulated under hypoxic conditions in cell culture, and a study has shown that the *PSEN2* variant influences the conformation of tau protein in human neuroblastoma cells.<sup>12,16</sup>

## **PSEN2 protein**

### **Structure**

*PSEN2* is located on chromosome 1, and it encodes the *PSEN2* protein. *PSEN2* is a transmembrane protein with 448 amino acids and a molecular weight of 55 Da.<sup>17,18</sup> It is predicted to span the lipid bilayer nine times.<sup>19</sup> *PSEN2* and *PSEN1* are homologous, with a similarity of 67%.<sup>20</sup> The two proteins differ at the N-terminus and at the hydrophilic loop, while the hydrophobic region is highly conserved. *PSEN2* is an unstable holoprotein. It undergoes autocatalytic endoproteolysis within the large cytoplasmic loop domain, to

form a stable and biologically active heterodimer. In *PSEN2*, two aspartyl residues—D263 and D366 found in the adjacent transmembrane regions Transmembrane domain (TM)-VI and TM-VII—are the active sites of the  $\gamma$ -secretase complex.

### **Location**

*PSEN2* has two isoforms. Isoform 1 is found in the placenta, skeletal muscle and heart, while isoform 2, which lacks amino acids 263–296, is found in the brain, heart, placenta, liver, skeletal muscle, and kidney. Presenilin proteins that are localized in neurons reside in the endoplasmic reticulum and Golgi.<sup>21</sup>


### **Function**

Presenilin, an aspartyl protease, is a subunit of  $\gamma$ -secretase.  $\gamma$ -Secretase participates in the cleavage of *APP*, which can produce different lengths of  $\beta$ -amyloid peptide ( $A\beta$ ). The  $A\beta_{42}$  form aggregates easier than the  $A\beta_{40}$  form. The accumulation of  $A\beta$  in the brain is a pathological characteristic of AD.<sup>22</sup> The process of  $A\beta$  aggregation is shown in Figure 1. *PSEN2* mutation might increase  $\gamma$ -secretase activity. Cell-based studies and mouse models have shown that some *PSEN2* mutations cause an increased production of  $A\beta_{42}$ , which is a major hallmark in the brains of patients with AD. Presenilin mutations are a major risk factor for AD.<sup>23</sup> Several studies have indicated that AD-related presenilin mutations can alter intracellular calcium signaling, which leads to  $A\beta$  aggregation to form brain plaques and neuronal cell death.<sup>24,25</sup>

$\gamma$ -Secretase catalyzes the intramembrane cleavage of integral membrane proteins. It plays an important role in intracellular signaling, including Notch signaling and *APP* processing. In separate studies published in 1996, Vito et al<sup>26</sup> and Wolozin et al<sup>27</sup> proposed that *PSEN2* is involved in apoptosis. A study demonstrated that wild-type and mutant N141I-*PSEN2* trigger p53-dependent apoptosis in HEK293 human cells and in murine neurons.<sup>28</sup> In primary rat cortical neurons, *PSEN2*, overexpression significantly increased susceptibility to staurosporine-induced apoptosis. *PSEN2* mutations can promote apoptosis. Bcl-2 can down regulate pro-apoptotic activities, which are induced by *PSEN2*.<sup>29</sup> A recent study suggested that overexpression of human mutant *PSEN2* induces changes in glucose metabolism, which is accompanied by a decrease in insulin levels.<sup>30</sup>

## **PSEN2 mutations**

Mutations in the presenilin genes are the main causes of familial EOAD. Similar to *APP*, mutant presenilins can enhance  $A\beta$  production and contribute to AD development, whereas *PSEN2* plays less of a role than *PSEN1*. An extensive literature search for mutations in *PSEN2* was conducted. As



**Figure 1** The process of A $\beta$  aggregation.

**Notes:** Amyloid precursor protein (APP) is a transmembrane protein. APP processing includes non-amyloidogenic and amyloidogenic pathways. Non-amyloidogenic pathway (left): APP is cleaved by  $\alpha$ -secretase in the middle of A $\beta$  with production soluble APP $\alpha$  (sAPP $\alpha$ ) and C-terminal fragment  $\alpha$  (CTF $\alpha$ ). Then CTF $\alpha$  is hydrolyzed by  $\gamma$ -secretase to generate APP intracellular domain (AICD). Amyloidogenic pathway (right): APP is cleaved by  $\beta$ -secretase resulting in N-terminal soluble APP $\beta$  (sAPP $\beta$ ) leaving the C-terminal fragment  $\beta$  (CTF $\beta$ ) which is hydrolyzed by  $\gamma$ -secretase to yield A $\beta$  and AICD. Presenilin, nicastrin, anterior pharynx-defective 1 (APH-1) and presenilin enhancer 2 (PEN-2) are the parts of  $\gamma$ -secretase. PSEN mutation might increase  $\gamma$ -secretase activity to cause plaque forming.

**Abbreviations:** AICD, APP intracellular domain; APP, amyloid precursor protein; APH-1, anterior pharynx-defective 1; CTF $\alpha$ , C-terminal fragment  $\alpha$ ; CTF $\beta$ , C-terminal fragment  $\beta$ ; sAPP, soluble APP; PEN-2, presenilin enhancer 2.

of date, 38 mutations have been reported. The number of mutations identified in *PSEN1* is greater than five times this number.<sup>31</sup> Two *PSEN2* mutations, Glu126fs and Lys306fs, are frameshift mutations, and the others are nonsynonymous substitutions (Table 1). *PSEN2* mutations are associated with variable penetrance and a wide range in the age of disease onset, from 45 to 88.<sup>32,33</sup> *PSEN2* mutations are associated with both EOAD and LOAD. Only 17 of the 38 are predicted to be disease-causing mutations (Figure 2). Ten of the mutations are not pathogenic and the others are still unclear. Sixteen mutations are located within transmembrane domains. Cell-based studies suggest that four of these mutations, T122P, N141I, M239I, and M239V, cause an increase in the amount of A $\beta$  peptide.<sup>34</sup> The mutations T122R, S130L, and M239I were found to alter calcium signaling.<sup>35–37</sup> Most of these mutations were discovered in European and African populations. Until now, only four missense mutations were described in Asian populations: Asn141Tyr was associated with EOAD in a Chinese Han family;<sup>37</sup> Gly34Ser was found in a Japanese patient;<sup>39</sup> and

Arg62Cys and Val214Leu were described in the Korean patients.<sup>6</sup>

## Related diseases

It was well-known that some mutations in *PSEN2* cause familial AD, while some *PSEN2* mutations are associated with other disorders, including DLB, FTD, breast cancer, DCM, and Parkinson's disease with dementia (PDD).

## Dementia with Lewy body

DLB is a progressive degenerative disease, accounting for 10%–20% of all dementias. The core clinical features of DLB are fluctuating cognition, recurrent visual hallucinations, and motor features of Parkinson's disease.<sup>40</sup> Lewy bodies, an abnormal aggregation of protein, are found throughout the brain of DLB patients and in patients with other brain disorders, including AD and PDD. In 2008, a *PSEN2* missense mutation, a C-to-T substitution at the second position of codon 85 leading to an alanine to valine substitution in the transcribed protein, was found in a proband with the

**Table I** PSEN2 mutations

Codon	Mutation	Exon	Protein domain	Phenotype	Pathogenicity	Biological effect	Country/ethnicities	References
29	Arg>His	EX3	N-Term	AD	No	Unknown	Mandinka	41
34	Gly>Ser	EX3	N-Term	LOAD	Unclear	No change in the A $\beta$ 42/A $\beta$ 40 ratio	Dutch/Japan	42
62	Arg>Cys	EX4	N-Term	EOAD	Unclear	Unknown	Dutch/Korea (Bagyinszky E, Department of Bionano Technology, Gachon University, personal communication, December 12, 2014)	42–44
62	Arg>His	EX4	N-Term	Sporadic EOAD/FTD/LOAD/Breast cancer/PD/DLB	No	No change in proteolytic products PSEN2-CTF and PSEN2-NTF; no change in A $\beta$ 42 levels or the A $\beta$ 42/A $\beta$ 40 ratio	Dutch/Italy/Africa/Turkey	34, 41, 45–49
69	Pro>Ala	EX4	N-Term	AD	Unclear	Unknown	Serbian	50
71	Arg>Trp	EX4	N-Term	LOAD/Breast cancer/Probable DLB/Breast cancer/control	Unclear	No change in A $\beta$ 42 levels	Dutch/Africa/Belgium/Turkey	42, 43, 47–49, 43, 51
85	Ala>Val	EX4	N-Term	DLB	Yes	Unknown	Italy	52
122	Thr>Pro	EX5	HL-I	EOAD	Yes	No change in proteolytic products PSEN2-CTF and PSEN2-NTF; increased A $\beta$ 42; increase A $\beta$ 42/A $\beta$ 40 ratio	Germany	31, 53, 54
122	Thr>Arg	EX5	HL-I	Atypical Dementia	Yes	Reduced calcium ion release from intracellular stores	Italy	35, 55, 56
126	Glu>fs	EX5	HL-I	AD	Yes	Unknown	Africa/Moroccan	57
126	Glu>Lys	EX5	HL-I	AD	Yes	Unknown	Germany	58
130	Ser>Leu	EX5	HL-I	FAD/DCM/sporadic LOAD	Unclear	No change in proteolytic products PSEN2-CTF and PSEN2-NTF; no change in A $\beta$ 42 levels or the A $\beta$ 42/A $\beta$ 40 ratio	Italy/Turkey/England	34, 47, 36, 59–62
139	Val>Met	EX5	HL-I	Familial LOAD	Unclear	Unknown	Italy	63
141	Asn>Ile	EX5	TM-II	FAD/LOAD	Yes	No change in proteolytic products PSEN2-CTF and PSEN2-NTF; increased A $\beta$ 42; increased A $\beta$ 42/A $\beta$ 40 ratio	Volga German/Spain	34, 8, 64, 65
141	Asn>Tyr	EX5	TM-II	AD	Yes	Unknown	People's Republic of China	38
143	Leu>His	EX5	TM-II	AD	No	Unknown	Bantu	41
148	Val>Ile	EX5	TM-II	LOAD	Yes	No change in proteolytic products PSEN2-CTF and PSEN2-NTF; no change in A $\beta$ 42 levels or the A $\beta$ 42/A $\beta$ 40 ratio	Spain	34, 66
161	Lys>Arg	EX5	HL-II	AD	Yes	Unknown	French	51
163	Arg>His	EX5	HL-II	Early cortical dysfunction	No	Unknown	Swedish	67
174	Met>Val	EX6	TM-III	EOAD	No	Unknown	Africa/Turkey	41, 48, 68
175	Ser>Cys	EX6	TM-III	FAD	Yes	Unknown	Italy	69
191	Val>Glu	EX7	HL-III	PDD	Unclear	Unknown	Belgium	70
214	Val>Leu	EX7	TM-IV	AD	Unclear	Unknown	Korea	6
228	Gln>Leu	EX7	TM-V	EOAD	Yes	Unknown	Poland	24
231	Tyr>Cys	EX7	TM-V	FTD	Yes	Unknown	Italy	71
235	Ile>Phe	EX7	TM-V	AD	No	Unknown	Caribbean Hispanics	72
237	Ala>Val	EX7	TM-V	AD	Unclear	Unknown	UK	73

(Continued)

**Table I** (Continued)

Codon	Mutation	Exon	Protein domain	Phenotype	Pathogenicity	Biological effect	Country/ethnicities	References
239	Met>Ile	EX7	TM-V	EOAD/FAD	Yes	No change in proteolytic products PSEN2-CTF and PSEN2-NTF; increased A $\beta$ 42; increased A $\beta$ 42/A $\beta$ 40 ratio; reduced calcium release	Italy	34, 35, 37, 74–76
239	Met>Val	EX7	TM-V	FAD	Yes	No change in proteolytic products PSEN2-CTF and PSEN2-NTF; increased A $\beta$ 42; increased A $\beta$ 42/A $\beta$ 40 ratio	Italy	34, 51, 64, 77
252	Ala>Thr	EX7	TM-VI	AD	No	Unknown	Mandenka	41
301	Thr>Met	EX9	HL-VI	AD	Unclear	No change in A $\beta$ 42/A $\beta$ 40 ratio	the Netherlands	78
306	Lys306fs	EX9	HL-VI	AD	Yes	Unknown	Africa/Moroccan	57
334	Pro>Ala	EX10	HL-VI	AD	No	Unknown	Caribbean Hispanics	72
334	Pro>Arg	EX10	HL-VI	AD/familial LOAD	No	Unknown	Spain	79
377	Ala>Val	EX11	TM-VII	AD	No	Unknown	Caribbean Hispanics	72
393	Val>Met	EX11	TM-VIII	AD	Unclear	No change in A $\beta$ 42 levels or the A $\beta$ 42/A $\beta$ 40 ratio	Danish	80, 81
430	Thr>Met	EX12	TM-IX	FAD/EOAD	Yes	Unknown	Spain	82, 83
439	Asp>Ala	EX12	C-Term	EOAD/FAD	Yes	No change in proteolytic products PSEN2-CTF and PSEN2-NTF; no change in A $\beta$ 42 levels or the A $\beta$ 42/A $\beta$ 40 ratio	Spain	34, 84


**Abbreviations:** A $\beta$ ,  $\beta$ -amyloid peptide; AD, Alzheimer's disease; EX, exon; FAD, familial Alzheimer's disease; DCM, dilated cardiomyopathy; EOAD, early-onset AD; LOAD, late-onset AD; PDD, Parkinson's disease with dementia; PSEN2, presenilin2.

clinical phenotype of Lewy body dementia. Neuropathological examination of the proband showed a mass of cortical Lewy bodies and hallmark lesions of AD. In his family, this mutation was identified in six carriers across two generations, with variable clinical presentation. Except for a young family member that was still asymptomatic, all carriers of the A85V mutation developed AD, DLB, or both. None of the patients carried other mutations in AD-related genes. The pathological *PSEN1* mutation, A79V, is homologous to the A85V mutation in *PSEN2*.<sup>85</sup> Sequence phylogenetic analysis suggested that the A85 residue is highly conserved. The mutation is located on the N-terminal, cytoplasmic side, adjacent to the TM-I domain that might be critical for the protein function. Overall, it was predicted that the A85V mutation is pathogenic. In all family members with *PSEN2* A85V, the genotype of apolipoprotein E (*ApoE*) was  $\epsilon$ 3/ $\epsilon$ 3, which suggests that  $\alpha$ -synuclein pathological structures are linked to *PSEN2* A85V without affecting the *ApoE*  $\epsilon$ 4 allele.<sup>52</sup> A *PSEN2* mutation, R71W, was reported in a 73-year-old European patient with cognitive impairment and extrapyramidal symptoms, which was likely undiagnosed for DLB. One of the proband's brothers also carried the R71W mutation and suffered an unspecified

type of dementia. The other brother was healthy and did not have a *PSEN2* mutation. The R71W mutation was previously identified in AD patients predicted to be possible pathogenic.<sup>70</sup> A *PSEN2* mutation, R62H, presented in a DLB patient, with no history of neurological diseases, who showed extrapyramidal signs was characterized by a slight left arm rest tremor, bilateral upper limb postural tremor, and bradykinesia on the left side.<sup>86</sup> This mutation, located in the N-terminal of *PSEN2*, is conserved between *PSEN1* and *PSEN2*. Walker et al showed that the R62H mutation did not affect A $\beta$ 42 levels or the A $\beta$ 42/A $\beta$ 40 ratio.<sup>34</sup> Guerreiro et al used PolyPhen-2 to show that the R62H variant is likely benign.<sup>41</sup> Based on these data, it is highly probably that *PSEN2* R62H can be characterized as “not pathogenic”. Since the age of onset in carriers of the R62H mutation is significantly earlier than in affected non-carriers even after correcting for *ApoE* genotype, the R62H mutation may function as a disease modifier.<sup>48</sup>

## Breast cancer

Breast cancer is the most common malignancy among women in Europe and the US. Two *PSEN2* mutations, R62H and R71W, have been identified in patients with breast cancer.



**Figure 2** Missense mutations in PSEN2 and their pathogenicity.  
**Abbreviations:** SNP, single nucleotide polymorphism; EX, exon.

The mutations are located in the hydrophilic, N-terminal domain. In HEK293 cells, the R62H and R71W mutations did not affect the levels of the PSEN2-CTF and PSEN2-NTF proteolytic products or the A $\beta$ (42)/A $\beta$ (40) ratio, but did influence PSEN2 stability. Full-length PSEN2 degenerated rapidly. In a study using transgenic *Caenorhabditis elegans*, the R62H and R71W mutations compromised PSEN2 function in Notch signaling.<sup>49</sup> PSEN2 has several potential roles in cancer. Deng et al and Wolozin et al reported that PSEN2 has pro-apoptotic activity.<sup>27,87</sup> A study also has shown that PSEN2 can also adjust  $\beta$ -catenin levels and act in a p53-dependent mechanism to regulate cell growth.<sup>49</sup> In 2013, a study suggested a significant role for  $\gamma$ -secretase in breast cancer.<sup>88</sup>

## Frontotemporal dementia

FTD, a clinical phenotype of frontotemporal lobar degeneration, is the second most common form of early-onset (<65 years) neurodegenerative disease after AD.<sup>89</sup> It is mainly characterized by deterioration of behavior, personality, and language abilities.<sup>89,90</sup> The prevalence of FTD is between 10% and 30% of all presenile dementia.<sup>91–96</sup> FTD has a number of clinical phenotypes and pathological

subtypes.<sup>3,97,98</sup> Clinical and molecular overlaps between AD and FTD or FTD-like phenotypes have been reported.<sup>99</sup> To date, at least four *PSEN2* mutations have been found in FTD patients. In 2010, *PSEN2* R62H was found in a 31-year-old patient. The patient's healthy mother also carried this mutation. The interaction of the H1 *MAPT* haplotype and the *ApoE*  $\epsilon$ 2 allele might function as a protective modifier against FTD, while the H1 *MAPT* haplotype unaccompanied by the *ApoE*  $\epsilon$ 2 might be a risk enhancer for FTD.<sup>43,100</sup> These possibilities imply that modifier, suppressor, and enhancer effects of multiple genes may be crucial for genetic analysis.

## Dilated cardiomyopathy

DCM is a heart muscle disease in which the heart becomes enlarged and cannot pump blood efficiently. DCM usually leads to heart failure. The causative factor for DCM has not been determined, but DCM in families is genetically linked. In 2006, the *PSEN2* S130L mutation was identified in two Caucasian families. It is highly conserved. Several family members with this mutation suffered DCM and heart failure.<sup>36</sup> Presenilin is expressed in multiple tissues, including in the heart, and it is required for cardiac development.<sup>101–104</sup> Calcium signaling was altered in cultured skin fibroblasts

from carriers of the mutation. The *PSEN1* D333G also was identified in a DCM patient. Compared to the phenotypes seen in carriers of *PSEN1* D333G, the phenotypes are milder in carriers of *PSEN2* S130L, and *PSEN2* S130L is not associated with heart failure as often. Currently, it is not clear whether  $\gamma$ -secretase activity is related to DCM. The Notch family of proteins is one of the major transcriptional regulators of cardiac growth and development.<sup>105</sup> Disordered Notch signaling is associated with valvular abnormalities, syndromic cardiovascular disease, congenital heart disease, and myocyte dysfunction.<sup>106</sup> *PSEN2* knockout (PS2KO) mice grow normally without cardiac hypertrophy and fibrosis, while cardiac contractility improved.<sup>107</sup> *PSEN2* plays an important role in cardiac systolic function by modulating  $\text{Ca}^{2+}$  signaling.

## Parkinson disease with dementia

Parkinson's disease (PD) was first described by James Parkinson in 1817. PD is a chronic, progressive, neurological disease that results from the destruction of nerve cells in the basal ganglia. The disease mainly affects movement, but as the neurological damage progresses, the disease often affects mental functions. PDD is an impairment in thinking and reasoning that eventually affects many people with PD. A 77-year-old carrier of *PSEN2* V191E showed the PDD phenotype characterized by cognitive decline, visual hallucinations, and confusion during the final years of the PD. This *PSEN2* mutation is located at a highly conserved amino acid residue in the protein. In a study by Bram Meeus, the V191E mutation did not exist in more than 1,200 control individuals, so he predicted that V191E is a damaging mutation.<sup>70</sup> A *PSEN2* R163H variant has been reported in a Swedish PD family in who were also found a de novo  $\alpha$ -synuclein A53T mutation. The proband's mother also carried the mutation *PSEN2* R163H, but she was healthy. Nevertheless, this mutation cannot be excluded with certainty as a cause of PD when in combination with  $\alpha$ -synuclein.<sup>67</sup> *PSEN2* S130L was identified in a patient with of LOAD, and his two siblings were diagnosed with PD. Unfortunately, the genetic results from the siblings are not available. The S130L mutation was also detected in the proband's two unaffected children, but the segregation of the disease could not be determined. The correlation between PD and AD is not clear.

## Conclusion

This review described mutations in *PSEN2* from diverse disorders. Mutations in *PSEN2* were shown to be a rare cause of familial AD. Pathogenic mutations in the *PSEN1*, *PSEN2*, and *APP* gene account for 18%–50% of familial EOAD cases

with autosomal dominant pattern of inheritance.<sup>108</sup> *PSEN2* genetic testing results could provide genetic counseling for patient's family members. There is a considerable interest in the application of this genetic information in medical practice through genetic testing and counseling. *PSEN2* mutations are involved in not only AD but also in other disorders, including FTD, DLB, PDD, breast cancer, and DCM. Why are *PSEN2* mutations found in multiple diseases? Are these diseases related? Until now, the answer to this question has been unclear. There are several possible reasons that *PSEN2* is associated with multiple diseases. *PSEN2* is a transmembrane protein that is a component of  $\gamma$ -secretase intramembrane protease.  $\gamma$ -Secretase is required to process several types of integral membrane proteins, and is involved in different signaling pathways. Mutations in *PSEN2* may disrupt the normal pathways and lead to different disorders. Thus, it can be hypothesized that these disorders might share underlying genetic factors. On the other hand, different neurodegenerative diseases show slightly different behavioral, language, and motor symptoms. Sometimes it is difficult to distinguish them clearly by clinical diagnosis. Many patients with both PDD and DLB have hallmark changes in the brain, including plaques and tangles that are associated with AD. These observations suggest that there may be a common pathogenetic mechanism in the formation of aggregated proteins. Therefore, mutations in *PSEN2* might play a role in  $\text{A}\beta$ ,  $\alpha$ -synuclein, and tau aggregation.

Overall, genetic studies have already indicated that *PSEN2* may affect people with FTD, PDD, LBD, breast cancer, and DCM. How presenilin 2 is implicated in the pathogenesis of these diseases is still unclear. This question needs to be further explored.

## Acknowledgment

This manuscript was supported by grants from the Gachon University Gil Medical Center (grant number 2013-30) and the Korea Health Technology R&D Project (HI14C3331) through the Korea Health Industry Development Institute (KHIDI), Ministry of Health & Welfare, Republic of Korea.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Hardy J. A hundred years of Alzheimer's disease research. *Neuron*. 2006; 52(1):3–13.
2. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. *J Geriatr Psychiatry Neurol*. 2010;23(4):213–227.

3. Żekanowski C, Styczyńska M, Pepłońska B, et al. Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland. *Exp Neurol*. 2003;184(2):991–996.
4. Bagyinszky E, Youn YC, An SS, Kim SY. The genetics of Alzheimer's disease. *Clin Interv Aging*. 2014;9:535–551.
5. Alzheimer Disease and Frontotemporal Dementia Mutation Database [homepage on the Internet]. Available from: <http://www.molgen.ua.ac.be/admutations>. Accessed February 16, 2015.
6. Youn YC, Bagyinszky E, Kim H, Choi BO, An SS, Kim S. Probable novel PSEN2 Val214Leu mutation in Alzheimer's disease supported by structural prediction. *BMC Neurol*. 2014;14(1):105.
7. Ertekin-Taner N. Genetics of Alzheimer's disease: a centennial review. *Neurol Clin*. 2007;25(3):611–667.
8. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science*. 1995;269(5226):973–977.
9. Renbaum P, Beeri R, Gabai E, et al. Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells. *Gene*. 2003;318:113–124.
10. Ounallah-Saad H, Beeri R, Goshen I, Yirmiya R, Renbaum P, Levy-Lahad. Transcriptional regulation of the murine Presenilin-2 gene reveals similarities and differences to its human orthologue. *Gene*. 2009;446(2):81–89.
11. Hendrickx A, Pierrot N, Tasiaux B, et al. Epigenetic induction of EGR-1 expression by the amyloid precursor protein during exposure to novelty. *PLoS One*. 2013;8(9):e74305.
12. Sato N, Hori O, Yamaguchi A, et al. A novel presenilin-2 splice variant in human Alzheimer's disease brain tissue. *J Neurochem*. 1999;72(6):2498–2505.
13. Sato N, Imaizumi K, Manabe T, et al. Increased production of beta-amyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin 2. *J Biol Chem*. 2001;276(3):2108–2114.
14. Smith MJ, Sharples RA, Evin G, et al. Expression of truncated presenilin 2 splice variant in Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex. *Mol Brain Res*. 2004;127(1):128–135.
15. Sato H, Takeuchi T, Sakai KL. Temporal cortex activation during speech recognition: an optical topography study. *Cognition*. 1999;73(3):B55–B66.
16. Nishikawa A, Manabe T, Katayama T, et al. Novel function of PS2V: change in conformation of tau proteins. *Biochem Biophys Res Commun*. 2004;318(2):435–438.
17. De Strooper B, Beullens M, Contreras B, et al. Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins. *J Biol Chem*. 1997;272(6):3590–3598.
18. Li J, Xu M, Zhou H, et al. Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation. *Cell*. 1997;90(5):917–927.
19. Li X, Dang S, Yan C, et al. Structure of a presenilin family intramembrane aspartate protease. *Nature*. 2013;493(7430):56–61.
20. Rademakers R, Cruts M, Van Broeckhoven C. Genetics of early-onset Alzheimer dementia. *Sci World J*. 2003;3:497–519.
21. Annaert WG, Levesque L, Craessaerts K, et al. Presenilin 1 controls  $\gamma$ -secretase processing of amyloid precursor protein in pre-Golgi compartments of hippocampal neurons. *J Cell Biol*. 1999;147(2):277–294.
22. De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and  $\gamma$ -secretase: structure, function, and role in Alzheimer disease. *Cold Spring Harb Perspect Med*. 2012;2(1):a006304.
23. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid  $\beta$ -protein in both transfected cells and transgenic mice. *Nature Med*. 1997;3(1):67–72.
24. Leissring MA, Yamasaki TR, Wasco W, et al. Calsenilin reverses presenilin-mediated enhancement of calcium signaling. *Proc Natl Acad Sci U S A*. 2000;97(15):8590–8593.
25. Leissring MA, LaFerla FM, Callamaras N, et al. Subcellular mechanisms of presenilin-mediated enhancement of calcium signaling. *Neurobiol Dis*. 2001;8(3):469–478.
26. Vito P, Wolozin B, Ganjei JK, et al. Requirement of the Familial Alzheimer's Disease Gene PS2 for Apoptosis OPPOSING EFFECT OF ALG-3. *Journal of Biological Chemistry*. 1996;271(49):31025–31028.
27. Wolozin B, Iwasaki K, Vito P, et al. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. *Science*. 1996;274(5293):1710–1713.
28. Da Costa CA, Paitel E, Mattson MP, et al. Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons. *Proc Natl Acad Sci U S A*. 2002;99(6):4043–4048.
29. Araki W, Yuasa K, Takeda S, et al. Pro-apoptotic effect of presenilin 2(PS2) overexpression is associated with down-regulation of Bcl-2 in cultured neurons. *J Neurochem*. 2001;79(6):1161–1168.
30. Lee YJ, Kim JE, Hwang IS, et al. Alzheimer's phenotypes induced by overexpression of human presenilin 2 mutant proteins stimulate significant changes in key factors of glucose metabolism[J]. *Mol Med Rep*. 2013;7(5):1571–1578.
31. Larner AJ. Presenilin-1 mutation Alzheimer's disease: a genetic epilepsy syndrome? *Epilepsy & Behavior*. 2011;21(1):20–22.
32. Bird TD, Levy-Lahad E, Poorkaj P, et al. Wide range in age of onset for chromosome 1-related familial Alzheimer's disease. *Ann Neurol*. 1996;40(6):932–936.
33. Sherrington R, Froelich S, Sorbi S, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. *Hum Mol Gen*. 1996;5(7):985–988.
34. Walker ES, Martinez M, Brunkan AL, et al. Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in A $\beta$  42/40 ratios. *J Neurochem*. 2005;92(2):294–301.
35. Zatti G, Burgo A, Giacomello M, et al. Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. *Cell Calcium*. 2006;39(6):539–550.
36. Li D, Parks SB, Kushner JD, et al. Mutations of presenilin genes in dilated cardiomyopathy and heart failure. *Am J Hum Genet*. 2006;79(6):1030–1039.
37. Zatti G, Ghidoni R, Barbiero L, et al. The presenilin 2 M239I mutation associated with familial Alzheimer's disease reduces Ca<sup>2+</sup> release from intracellular stores. *Neurobiol Dis*. 2004;15(2):269–278.
38. Niu F, Yu S, Zhang Z, et al. A novel mutation in the PSEN2 gene (N141Y) associated with early-onset autosomal dominant Alzheimer's disease in a Chinese Han family. *Neurobiol Aging*. 2014;35(10):2420.e1–2420.e5.
39. Bai YF, Tian J, Quan WX, Maeda K. Association of mutations of presenilin-2 gene and sporadic Alzheimer's disease. *J Chin Med Univ*. 2011;40:357–363.
40. Kim TH. Diagnosis and management of dementia with Lewy bodies. *J Korean Geriatr Psychiatry*. 2012;16(2):75–81.
41. Guerreiro RJ, Baquero M, Blesa R, et al. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. *Neurobiol Aging*. 2010;31(5):725–731.
42. Sleegers K, Roks G, Theuns J, et al. Familial clustering and genetic risk for dementia in a genetically isolated Dutch population. *Brain*. 2004;127(7):1641–1649.
43. Brouwers N, Sleegers K, Van Broeckhoven C. Molecular genetics of Alzheimer's disease: an update. *Ann Med*. 2008;40(8):562–583.
44. Ertekin-Taner N, Younkin LH, Yager DM, et al. Plasma amyloid  $\beta$  protein is elevated in late-onset Alzheimer disease families. *Neurology*. 2008;70(8):596–606.
45. Cruts M, Van Duijn CM, Backhovens H, et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. *Hum Mol Genet*. 1998;7(1):43–51.
46. Gallo M, Tomaino C, Puccio G, et al. Novel MAPT Val75Ala mutation and PSEN2 Arg62His in two siblings with frontotemporal dementia. *Neurol Sci*. 2010;31(1):65–70.

47. Lohmann E, Guerreiro RJ, Erginel-Unaltuna N, et al. Identification of PSEN1 and PSEN2 gene mutations and variants in Turkish dementia patients. *Neurobiol Aging*. 2012;33(8):1850.e17–1850.e27.
48. Cruchaga C, Chakraverty S, Mayo K, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. *PLoS One*. 2012;7(2):e31039.
49. To MD, Gokgoz N, Doyle TG, et al. Functional characterization of novel presenilin-2 variants identified in human breast cancers. *Oncogene*. 2006; 25(25):3557–3564.
50. Dobricic V, Stefanova E, Jankovic M, et al. Genetic testing in familial and young-onset Alzheimer's disease: mutation spectrum in a Serbian cohort. *Neurobiol Aging*. 2012;33(7):1481.e7–1481.e12.
51. Wallon D, Rousseau S, Rovelet-Lecrux A, et al. The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. *J Alzheimers Dis*. 2012; 30(4):847–856.
52. Piscopo P, Marcon G, Piras MR, et al. A novel PSEN2 mutation associated with a peculiar phenotype. *Neurology*. 2008;70(17):1549–1554.
53. Finckh U, Müller-Thomsen T, Mann U, et al. High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. *Am J Hum Genet*. 2000; 66(1):110–117.
54. Finckh U, Kuschel C, Anagnostouli M, et al. Novel mutations and repeated findings of mutations in familial Alzheimer disease. *Neurogenetics*. 2005;6(2):85–89.
55. Binetti G, Signorini S, Squitti R, et al. Atypical dementia associated with a novel presenilin-2 mutation. *Ann Neurol*. 2003;54(6):832–836.
56. Giacomello M, Barbiero L, Zatti G, et al. Reduction of Ca<sup>2+</sup> stores and capacitative Ca<sup>2+</sup> entry is associated with the familial Alzheimer's disease presenilin-2 T122R mutation and anticipates the onset of dementia. *Neurobiol Dis*. 2005;18(3):638–648.
57. El Kadmiri N, Zaid N, Zaid Y, et al. Novel presenilin mutations within Moroccan patients with early-onset Alzheimer's disease. *Neuroscience*. 2014;269:215–222.
58. Müller U, Winter P, Bolender C, et al. Previously unrecognized missense mutation E126K of PSEN2 segregates with early onset Alzheimer's disease in a family. *J Alzheimers Dis*. 2014;42(1):109–113.
59. Tedde A, Nacmias B, Ciantelli M, et al. Identification of new presenilin gene mutations in early-onset familial Alzheimer disease. *Arch Neurol*. 2003;60(11):1541–1544.
60. Sorbi S, Tedde A, Nacmias B, et al. Novel presenilin 1 and presenilin 2 mutations in early-onset Alzheimer's disease families. *Neurobiol Aging*. 2002;23(1S):S312.
61. Tomaino C, Bernardi L, Anfossi M, et al. Presenilin 2 Ser130Leu mutation in a case of late-onset "sporadic" Alzheimer's disease. *J Neurol*. 2007;254(3):391–393.
62. Sassi C, Guerreiro R, Gibbs R, et al. Exome sequencing identifies 2 novel presenilin 1 mutations (p. L166V and p. S230R) in British early-onset Alzheimer's disease. *Neurobiol Aging*. 2014;35(10): 2422.e13–2422.e16.
63. Bernardi L, Tomaino C, Anfossi M, et al. Late onset familial Alzheimer's disease: novel presenilin 2 mutation and PS1 E318G polymorphism. *J Neurol*. 2008;255(4):604–606.
64. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. *Nature*. 1995;376(6543): 775–778.
65. Jayadev S, Leverenz JB, Steinbart E, et al. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. *Brain*. 2010;133(4):1143–1154.
66. Lao JI, Beyer K, Fernández-Novoa L, et al. A novel mutation in the predicted TM2 domain of the presenilin 2 gene in a Spanish patient with late-onset Alzheimer's disease. *Neurogenetics*. 1998;1(4): 293–296.
67. Puschmann A, Ross OA, Vilariño-Güell C, et al. A Swedish family with de novo  $\alpha$ -synuclein A53T mutation: Evidence for early cortical dysfunction. *Parkinsonism Relat Disord*. 2009;15(9):627–632.
68. Clarimón J, Guerreiro R, Lleó A, et al. Genetic screening in a large cohort of early-onset Alzheimer's disease patients from Spain: novel mutations in the amyloid precursor protein and presenilins. *Alzheimers Dement*. 2008;4(4):T583.
69. Piscopo P, Talarico G, Crestini A, et al. A novel mutation in the predicted TMIII domain of the PSEN2 gene in an Italian pedigree with atypical Alzheimer's disease. *J Alzheimers Dis*. 2010;20(1):43–47.
70. Meeus B, Verstraeten A, Crosiers D, et al. DLB and PDD: a role for mutations in dementia and Parkinson disease genes? *Neurobiol Aging*. 2012;33(3):629.e5–629.e18.
71. Marcon G, Di Fede G, Giaccone G, et al. A novel Italian presenilin 2 gene mutation with prevalent behavioral phenotype. *J Alzheimers Dis*. 2009;16(3):509–511.
72. Lee JH, Kahn A, Cheng R, et al. Disease-related mutations among Caribbean Hispanics with familial dementia. *Molecular Genet Genomic Med*. 2014;2(5):430–437.
73. Sassi C, Guerreiro R, Gibbs R, et al. Investigating the role of rare coding variability in Mendelian dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP) in late-onset Alzheimer's disease. *Neurobiol Aging*. 2014;35(12):2881.e1–2881.e6.
74. Finckh U, Alberici A, Antoniazzi M, et al. Variable expression of familial Alzheimer disease associated with presenilin 2 mutation M239I. *Neurology*. 2000;54(10):2006–2008.
75. Testi S, Fabrizi GM, Pompanin S, et al. Autosomal dominant Alzheimer's disease with early frontal lobe involvement associated with the Met239Ile mutation of Presenilin 2 gene. *J Alzheimers Dis*. 2012;31(1):7–11.
76. Tremolizzo L, Susani E, Mapelli C, et al. First report of PSEN2 mutation presenting as posterior cortical atrophy. *Alzheimer Dis Assoc Disord*. Epub 2014 Jul 9.
77. Marcon G, Giaccone G, Cupidi C, et al. Neuropathological and clinical phenotype of an Italian Alzheimer family with M239V mutation of presenilin 2 gene. *J Neuropath Exp Neurol*. 2004;63(3): 199–209.
78. Croes EA, Theuns J, Houwing-Duistermaat JJ, et al. Octapeptide repeat insertions in the prion protein gene and early onset dementia. *J Neurol Neurosurg Psychiatry*. 2004;75(8):1166–1170.
79. Lleó A, Castellví M, Blesa R, et al. Uncommon polymorphism in the presenilin genes in human familial Alzheimer's disease: not to be mistaken with a pathogenic mutation. *Neurosci Lett*. 2002;318(3): 166–168.
80. Lindquist SG, Hasholt L, Bahl JMC, et al. A novel presenilin 2 mutation (V393M) in early-onset dementia with profound language impairment. *Eur J Neurol*. 2008;15(10):1135–1139.
81. Lindquist SG, Schwartz M, Batbayli M, et al. Genetic testing in familial AD and FTD: mutation and phenotype spectrum in a Danish cohort. *Clin Genet*. 2009;76(2):205–209.
82. Lleó A, Blesa R, Queralt R, et al. Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. *Arch Neurol*. 2002;59(11):1759–1763.
83. Ezquerro M, Lleó A, Castellví M, et al. A novel mutation in the PSEN2 gene (T430M) associated with variable expression in a family with early-onset Alzheimer disease. *Arch Neurol*. 2003;60(8): 1149–1151.
84. Lleo A, Blesa R, Gendre J, et al. A novel presenilin 2 gene mutation (D439A) in a patient with early-onset Alzheimer's disease. *Neurology*. 2001;57(10):1926–1928.
85. Kauwe JSK, Jacquart S, Chakraverty S, et al. Extreme cerebrospinal fluid amyloid  $\beta$  levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. *Ann Neurol*. 2007;61(5):446–453.
86. Raciti L, Nicoletti A, Le Pira F, et al. Presenilin-2 gene mutation presenting as Lewy body dementia? *Neurol Sci*. 2011;32(3):533–534.
87. Deng G, Pike CJ, Cotman CW. Alzheimer-associated presenilin-2 confers increased sensitivity to apoptosis in PC12 cells. *FEBS Lett*. 1996; 397(1):50–54.
88. Peltonen HM, Haapasalo A, Hiltunen M, Kataja V, Kosma VM, Mannermaa A.  $\gamma$ -Secretase components as predictors of breast cancer outcome. *PLoS One*. 2013;8(11):e79249.

89. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology*. 1998; 51(6):1546–1554.
90. Hodges JR. Frontotemporal dementia (Pick's disease): clinical features and assessment. *Neurology*. 2001;56(Suppl 4):S6–S10.
91. Ratnavalli E, Brayne C, Dawson K, et al. The prevalence of frontotemporal dementia. *Neurology*. 2002;58(11):1615–1621.
92. Cairns NJ. Neuronal intermediate filament inclusion disease. *Handb Clin Neurol*. 2008;89:443–448.
93. Snowden JS. Frontotemporal dementia. *Br J Psychiatry*. 2002;180: 140–143.
94. Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. *CNS Drugs*. 2010;24(5):375–398.
95. Borroni B, Alberici A, Archetti S, et al. New insights into biological markers of frontotemporal lobar degeneration spectrum. *Curr Med Chem*. 2010;17(10):1002–1009.
96. Rosso SM, Roks G, Stevens M, et al. Complex compulsive behaviour in the temporal variant of frontotemporal dementia. *J Neurol*. 2001;248(11):965–970.
97. Hodges JR, Miller B. The neuropsychology of frontal variant frontotemporal dementia and semantic dementia. Introduction to the special topic papers: part II. *Neurocase*. 2001;7(2):113–121.
98. Mackenzie IRA, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. *Acta Neuropathol*. 2010;119(1):1–4.
99. Lindquist SG, Brændgaard H, Svenstrup K, et al. Frontotemporal dementia linked to chromosome 3 (FTD-3) – current concepts and the detection of a previously unknown branch of the Danish FTD-3 family. *Eur J Neurol*. 2008;15(7):667–670.
100. Bernardi L, Maletta RG, Tomaino C, et al. The effects of APOE and tau gene variability on risk of frontotemporal dementia. *Neurobiol Aging*. 2006;27(5):702–709.
101. Levy-Lahad E, Poorkaj P, Wang K, et al. Genomic structure and expression of STM2, the chromosome 1 familial Alzheimer disease gene. *Genomics*. 1996;34(2):198–204.
102. Hébert SS, Serneels L, Dejaegere T, et al. Coordinated and widespread expression of  $\gamma$ -secretase in vivo: evidence for size and molecular heterogeneity. *Neurobiol Dis*. 2004;17(2):260–272.
103. Nakajima M, Moriizumi E, Koseki H, et al. Presenilin 1 is essential for cardiac morphogenesis. *Dev Dyn*. 2004;230(4):795–799.
104. Donoviel DB, Hadjantonakis AK, Ikeda M, et al. Mice lacking both presenilin genes exhibit early embryonic patterning defects. *Genes Dev*. 1999;13(21):2801–2810.
105. Hansson EM, Lendahl U, Chapman G. Notch signaling in development and disease. *Semin Cancer Biol*. 2004;14(5):320–328.
106. Nosedá M, McLean G, Niessen K, et al. Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. *Circ Res*. 2004;94(7):910–917.
107. Takeda T, Asahi M, Yamaguchi O, et al. Presenilin 2 regulates the systolic function of heart by modulating  $Ca^{2+}$  signaling. *FASEB J*. 2005;19(14): 2069–2071.
108. Kowalska A. Genetic counseling and testing for families with Alzheimer's disease. *Neurol Neurochir Pol*. 2004;38(6):495–501.

## Clinical Interventions in Aging

### Publish your work in this journal

Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings. This journal is indexed on PubMed Central, MedLine,

CAS, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/clinical-interventions-in-aging-journal>

Dovepress